IT HAS been estimated (Annotation, 1962) that in any given week in Great Britain alone, 100,000 people are taking phenylbutazone. There are several well known side effects from this drug, and a considerable number of cases in which marrow depression has occurred have already been reported (Leonard, 1953; Kersley and Mandell, 1963;  Kaplin, 1955; Venning, 1957; Hale and DeGruchy, 1960; Rankin, 1961; Lander and Bonnin, 1962; McCarthy and Chalmers, 1964; Humble, 1964; Woodliff and Dougan, 1964) . Our seardh of the literature has revealed 15 cases of aplastic anaemia in patients taking phenylibutazone; in 7 of these cases the marrow failure proved fatal.
We record the following case of fatal aplastic anaemia because it re-emphasilses the possible dangers of this drug and the need for extreme wariness when it is being used.
Case Report
A 79-year-old widow was admitted to hospital on the 6th of November, 1964. Pernicious anaemia had been diagnosed in 1954 and had been well controlled with cytamen given every three weeks. About the end of 1963 she had complained of "arthritic pains" in the hands and legs, and her own doctor prescribed phenylbutazone, 100 mg. tablets, one thrice daily. In fact she took the tablets rather erratically, so that the total amount taken over a period of quite marked subjective improvement, but bruising increased in the buccal cavity. The platelet count rose to 90,000/ cu. mm. On the seventh day, further transfusion was given because the haemoglobin was still only 7.7 g. /100 ml. Despite further transfusion to a total of 12 pints haemoglo,bin and platelet counts steadily dropped, and on the tenth day from admission she became comatose, and died a few hours later. The immediate cause of death was thought to be brain stem haemorrhage.
Necropsy: Death was due to multiple haemorrhages resulting from thrombocytopenia. Externally there were extensive petechiae over the arms and legs, and a large ecchymosis on the lower lip. The meninges showed extensive subdural haemorrahges up to 5 mm. in thickness, covering the whole of the vault and base of the skull. There was evident pulmonary oedema. The heart was of normal size, and coronary arteries normal. The stomach contained approximately 200 ml. of fresih blood but was otherwise normal. The small intestine was distended with blood but the large intestine was normal. The spleen was of normal size and architecture; both adrenals were normal; the kidneys were pale and the pelves filled with fresh blood. The bladder contained bloodstained urine. Discussion Leonard (1953) has summarised some of the non-haentatological complications associated with phenylbutazone. Sodium and water retention may cause oedema and precipitate cardiac failure. Nausea, vomiting and diarrhoea are common but not serilolus; of more importance is possible re-
aetivalion of peptic ulcer, which may result in haematemesis and melaena. Skin rashes have occurred frequently, and jaundice rarely. Mauer (1955) and more recently McCarthy and Chalmers (1964) have given excellent reviews of the haenTatologicall complications of phenylbutazone therapy, and to date there have been some 85 cases of such complications pulblished in the Englishh literature. These are summarised in the table, in which the present case has been added, making the total cases 86, of which 20 have ibeen fatal. We have added our case because it seems an inescapable conclusion in view of the evidence presented that the marrow failure was due to phenylbutazone.
It is possible that the dose of phenylbutazone may bear little relationship to the development of haematological complications in any given case. In the present instance the estimated total was lOg. In the other reported cases the lowest total dose was 4g., the highest 300g. Moreover, intermittent therapy may be just as dangerous, possibly due to a sensitisation mechanism in the marrow (Kersley and Mandell, 1953) .
We have been able to trace only one other example of aplastic anaemia, apparently due to phenylbutazone, in a patient proved to have pernicious anaemia (Lander and Bonnin, 1962) . This was the case of an elderly woman, who had taken phenylbutazone for nine months, and who 
